title: Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
abstract: OBJECTIVE
  To investigate the effects of a daily regimen of propiverine 20 mg in patients with an overactive bladder (OAB), focused on improving urgency, as the clinical efficacy of treatment for OAB should be measured in terms of urgency, the cornerstone symptom of OAB.
  
  
  METHODS
  Eligible patients aged > or = 18 years with symptoms of OAB were enrolled in this multicentre, prospective, parallel, double-blind, placebo-controlled trial. Of 264 patients (mean age 52.2 years), 221 who had efficacy data available from baseline and at least one on-treatment visit with >75% compliance with medication were analysed (142 in the propiverine group and 79 in the placebo group). All patients were randomized to receive a placebo or 20 mg propiverine once daily in a 12-week study. They completed a 3-day voiding diary before visits during the study period, including the severity of urgency associated with every voiding, using the Indevus Urgency Severity Scale and the Urgency Perception Score. The patients' overall self-evaluation of treatment benefits at the end of the study, and safety data, were also collected.
  
  
  RESULTS
  The daily urgency episodes reduced significantly from baseline to 12 weeks on propiverine treatment, compared with placebo (-46.0% vs -31.3%, P = 0.005). Secondary endpoints, including sum of urgency severity per 24 h, urgency severity per void, and daytime voiding frequency, were also improved significantly in the propiverine group. Overall, of those patients treated with propiverine, 38.7% rated their treatment as providing 'much benefit', compared with 15.2% of the placebo group (P = 0.025). Adverse events reported by 32 (22.5%) and 10 (12.7%) patients in the propiverine and placebo group were all tolerable. However, this is a short-term study using only one fixed regimen.
  
  
  CONCLUSIONS
  Propiverine 20 mg once-daily could be an effective treatment for patients with OAB, by improving urgency.
authors.affiliation: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Kyu-Sung
authors.initials: KS
authors.lastname: Lee
authors.forename: Hye Won
authors.initials: HW
authors.lastname: Lee
authors.forename: Myung-Soo
authors.initials: MS
authors.lastname: Choo
authors.forename: Jae-Seung
authors.initials: JS
authors.lastname: Paick
authors.forename: Jeong Gu
authors.initials: JG
authors.lastname: Lee
authors.forename: Ju Tae
authors.initials: JT
authors.lastname: Seo
authors.forename: Jeong Zoo
authors.initials: JZ
authors.lastname: Lee
authors.forename: Young-Suk
authors.initials: YS
authors.lastname: Lee
authors.forename: Hana
authors.initials: H
authors.lastname: Yoon
authors.forename: Choal Hee
authors.initials: CH
authors.lastname: Park
authors.forename: Yong-Gil
authors.initials: YG
authors.lastname: Na
authors.forename: Young Beom
authors.initials: YB
authors.lastname: Jeong
authors.forename: Jong Bouk
authors.initials: JB
authors.lastname: Lee
authors.forename: Won Hee
authors.initials: WH
authors.lastname: Park
mesh_terms: D000328:Adult; D000368:Aged; D001561:Benzilates / Q000008:administration & dosage* / Q000009:adverse effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D001561:Benzilates; D002121:Calcium Channel Blockers; D018727:Muscarinic Antagonists; C015586:propiverine